Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985660 | 1.00 | CHRNA7 (0.40) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL4986626 | 0.80 | DRD2 (0.50) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL4986638 | 0.80 | DRD2 (0.50) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL4985407 | 0.80 | HTR3A (0.48) | CHRNA7HTR3ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL4985415 | 0.80 | HTR3A (0.48) | CHRNA7HTR3ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL4989050 | 0.79 | HTR3A (0.42) | HTR3A | |
| SCHEMBL4989041 | 0.79 | HTR3A (0.42) | HTR3A | |
| SCHEMBL15441398 | 0.78 | CHRNB2 (0.58) | CHRNA7HTR3ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL15441397 | 0.78 | CHRNB2 (0.58) | CHRNA7HTR3ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL4991806 | 0.73 | HTR3E (0.39) | CHRNA7HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384954-B2 | 4-substituted imidazoles | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-7384954-B2 | 4-substituted imidazoles | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-7384954-B2 | 4-substituted imidazoles | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-20070105896-A1 | 4-Substituted imidazoles | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105896-A1 | 4-Substituted imidazoles | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105896-A1 | 4-Substituted imidazoles | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | US | disclosed |
| EP-1687303-A1 | 4-SUBSTITUTED IMIDAZOLES | AstraZeneca AB (SE) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049612-A1 | 4-SUBSTITUTED IMIDAZOLES | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105896-A1 | 4-Substituted imidazoles | GRIN2C, GRIN2D, GRIN2A | CHRNA7 108/4885HTR3A 712/4885HTR3E 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.